ZNF479: A Promising Drug Target and Biomarker for KRAB Zinc Finger Protein-Containing Diseases
ZNF479: A Promising Drug Target and Biomarker for KRAB Zinc Finger Protein-Containing Diseases
Abstract:
ZNF479, a member of the KRAB zinc finger gene family, has been identified as a potential drug target and biomarker for various diseases associated with KRAB zinc finger protein (KRAB-P) mutations. This article will discuss the molecular mechanisms underlying KRAB-P mutations , the prevalence of these mutations, and the potential therapeutic benefits of targeting ZNF479.
Introduction:
KRAB zinc finger proteins (KRAB-P) are a family of non-coding RNA-protein interactions that play a crucial role in various cellular processes, including cell signaling, chromosome structure, and gene regulation. The KRAB-P gene has four splice variants , KRAB-P1, KRAB-P2, KRAB-P3, and KRAB-P4, which result in the production of different isoforms with different protein sequences. These isoforms have been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders.
One of the most well-studied is the KRAB-P gene associated with the disease Menin-MLL. Menin-MLL is a genetic disorder that is characterized by the accumulation of DNA mutations, including mutations in the KRAB-P gene, in the MLL1 gene. Menin-MLL patients have a wide range of symptoms, including progressive muscle weakness, myocardial infarction, and visual impairment. The accumulation of mutations in the KRAB-P gene has been implicated in the pathogenesis of Menin-MLL.
In addition to Menin-MLL, KRAB-P mutations have also been implicated in various other diseases, including neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These mutations can lead to the misfolding and localization of KRAB-P proteins , which can cause a range of cellular and molecular changes that contribute to the development of these diseases.
The ZNF479 gene:
The ZNF479 gene is a non-coding RNA gene that is located within the KRAB-P gene cluster on chromosome 19. ZNF479 is a member of the KRAB zinc finger gene family and has four exons that encode the protein ZNF479. ZNF479 is predominantly expressed in the brain and nervous system, and its expression has been implicated in various cellular processes, including cell signaling, neuronal organization, and synaptic plasticity.
Expression of ZNF479:
ZNF479 is highly expressed in the brain and nervous system, and its expression has been implicated in the development and progression of various neurological disorders. ZNF479 has been shown to be involved in the regulation of neuronal excitability and synaptic plasticity, and it has been implicated in the development of neurodegenerative disorders.
Drug targeting ZNF479:
Targeting ZNF479 as a drug target has the potential to treat a wide range of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These diseases are characterized by the accumulation of mutations in the KRAB-P gene and the misfolding and localization of KRAB-P proteins.
The mechanism of action of ZNF479:
The mechanism of action of ZNF479 is not well understood, but it is thought to be involved in the regulation of neuronal excitability and synaptic plasticity. ZNF479 has been shown to be involved in the regulation of ion channels, including the voltage-dependent K+ channels, which are critical for the regulation of neuronal excitability.
In addition to its role in the regulation of ion channels, ZNF479 is also thought to be involved in the regulation of
Protein Name: Zinc Finger Protein 479
Functions: May be involved in transcriptional regulation
The "ZNF479 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF479 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ZNF48 | ZNF480 | ZNF483 | ZNF484 | ZNF485 | ZNF486 | ZNF487 | ZNF488 | ZNF490 | ZNF491 | ZNF492 | ZNF493 | ZNF496 | ZNF497 | ZNF497-AS1 | ZNF500 | ZNF501 | ZNF502 | ZNF503 | ZNF503-AS1 | ZNF503-AS2 | ZNF506 | ZNF507 | ZNF510 | ZNF511 | ZNF512 | ZNF512B | ZNF513 | ZNF514 | ZNF516 | ZNF516-DT | ZNF517 | ZNF518A | ZNF518B | ZNF519 | ZNF519P3 | ZNF521 | ZNF524 | ZNF525 | ZNF526 | ZNF527 | ZNF528 | ZNF528-AS1 | ZNF529 | ZNF529-AS1 | ZNF530 | ZNF532 | ZNF534 | ZNF536 | ZNF540 | ZNF541 | ZNF542P | ZNF543 | ZNF544 | ZNF546 | ZNF547 | ZNF548 | ZNF549 | ZNF550 | ZNF551 | ZNF552 | ZNF554 | ZNF555 | ZNF556 | ZNF557 | ZNF558 | ZNF559 | ZNF559-ZNF177 | ZNF560 | ZNF561 | ZNF561-AS1 | ZNF562 | ZNF563 | ZNF564 | ZNF565 | ZNF566 | ZNF566-AS1 | ZNF567 | ZNF568 | ZNF569 | ZNF56P | ZNF57 | ZNF570 | ZNF571 | ZNF571-AS1 | ZNF572 | ZNF573 | ZNF574 | ZNF575 | ZNF576 | ZNF577 | ZNF578 | ZNF579 | ZNF580 | ZNF582 | ZNF582-DT | ZNF583 | ZNF584 | ZNF585A | ZNF585B
